KLP Kapitalforvaltning
CTMX icon

KLP Kapitalforvaltning’s CytomX Therapeutics CTMX Stock Holding History

KLP Kapitalforvaltning’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$96.6K Hold
35,500
– – ﹤0.01% 2084
2026
Q2 		$133K Hold
35,500
– – ﹤0.01% 2028
2026
Q1 		$167K Buy
+35,500
New +$180K ﹤0.01% 1884

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

KLP Kapitalforvaltning's CTMX Position: Q3 2026 in Review

KLP Kapitalforvaltning held its CytomX Therapeutics (CTMX) position steady in Q3 2026 at 35,500 shares worth $96.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2084.

KLP Kapitalforvaltning first reported a position in CTMX in Q1 2026 and has held it in 3 quarters since. The position peaked at $167K in Q1 2026. 128 funds tracked by Wall St. Rank hold CTMX as of Q3 2026.

  • KLP Kapitalforvaltning held 35,500 shares of CytomX Therapeutics worth $96.6K as of Q3 2026.
  • KLP Kapitalforvaltning left its CytomX Therapeutics share count unchanged in Q3 2026.
  • CytomX Therapeutics made up ﹤0.01% of KLP Kapitalforvaltning's portfolio in Q3 2026, its #2084 holding.
  • KLP Kapitalforvaltning first reported a position in CytomX Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • KLP Kapitalforvaltning's CytomX Therapeutics position peaked at $167K in Q1 2026.
  • 128 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q3 2026, filed 10 Nov 2026.